Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 103402137 | 10340213 | 7 | F | 20160819 | 20140724 | 20160819 | EXP | FR-BRISTOL-MYERS SQUIBB COMPANY-21212477 | BRISTOL MYERS SQUIBB | 0.00 | F | Y | 2.88000 | KG | 20160819 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 103402137 | 10340213 | 1 | PS | REYATAZ | ATAZANAVIR SULFATE | 1 | Transplacental | 300 MG, QD | U | 21567 | 300 | MG | QD | ||||||
| 103402137 | 10340213 | 2 | C | TRUVADA | EMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Transplacental | 1 DF, QD | U | 0 | 1 | DF | QD | ||||||
| 103402137 | 10340213 | 3 | C | NORVIR | RITONAVIR | 1 | Transplacental | 100 MG, QD | U | 0 | 100 | MG | QD | ||||||
| 103402137 | 10340213 | 4 | C | METOCLOPRAMIDE. | METOCLOPRAMIDE | 1 | Transplacental | U | 0 | ||||||||||
| 103402137 | 10340213 | 5 | C | ONDANSETRON | ONDANSETRON | 1 | Transplacental | U | 0 | ||||||||||
| 103402137 | 10340213 | 6 | C | ESOMEPRAZOLE | ESOMEPRAZOLE | 1 | Transplacental | U | 0 | ||||||||||
| 103402137 | 10340213 | 7 | C | SERTACONAZOLE | SERTACONAZOLE | 1 | Transplacental | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 103402137 | 10340213 | 1 | Product used for unknown indication |
| 103402137 | 10340213 | 2 | Product used for unknown indication |
| 103402137 | 10340213 | 3 | Product used for unknown indication |
| 103402137 | 10340213 | 4 | Product used for unknown indication |
| 103402137 | 10340213 | 5 | Product used for unknown indication |
| 103402137 | 10340213 | 6 | Product used for unknown indication |
| 103402137 | 10340213 | 7 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 103402137 | 10340213 | OT |
| 103402137 | 10340213 | CA |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 103402137 | 10340213 | Arrhythmia | |
| 103402137 | 10340213 | Congenital central nervous system anomaly | |
| 103402137 | 10340213 | Epilepsy congenital | |
| 103402137 | 10340213 | Foetal distress syndrome | |
| 103402137 | 10340213 | Foetal exposure during pregnancy | |
| 103402137 | 10340213 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 103402137 | 10340213 | 1 | 20140327 | 0 | ||
| 103402137 | 10340213 | 2 | 20140327 | 0 | ||
| 103402137 | 10340213 | 3 | 20140327 | 0 |